Author

Maia S. Lineberry

Dana-Farber Cancer Institute

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Andrew A. LaneiD· 1 shared Benjamin K. Eschle· 1 shared David G. J. CucchiiD· 1 shared Erica A. K. DePasqualeiD· 1 shared Fadi J. NajmiD· 1 shared George I KaradimoviD· 1 shared Jacqueline Suen GarciaiD· 1 shared Jean AcostaiD· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Andrew A. LaneORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologybioRxivPreprintDec 20, 2024

Translation Initiation Represents an Acute Myeloid Leukemia Cell Vulnerability That Can Be Co-Targeted With BCL-2 Inhibition

Yoke Seng Lee, Jonathan Good, Noha Awais…·Peter van Galen

The paper identifies EIF4A1 as a vulnerability in AML cells and shows that combining Zotatifin with Venetoclax enhances apoptosis and survival in AML models.

DOI 10.1101/2024.12.20.629809

humanbulk RNA-seq

𝕏 PostBluesky